Home|Journals|Articles by Year|Audio Abstracts
 

Review Article

IJMDC. 2023; 7(5): 818-821


Safety and efficacy of favipiravir in COVID-19: a comprehensive literature review

Khalid M. Ahusayni, Salman A. Alharthi, Mona Y. Alhazmi, Shaima S. Alaithan, Yasir Alotaibi, Zahra A. Alhaddad, Alhanuf A. Alrowaished, Hissah A. Almousa, Abdulaziz A. Hakami, Yasmin B. Alotaibi.




Abstract

The severe acute respiratory syndrome coronavirus 2 virus spread fast around the globe. The medical community is actively searching for an antiviral that could be effective against it. An antiviral drug called favipiravir, created for the treatment of influenza, may work well for coronavirus disease 2019 (COVID-19). Therefore, this study evaluated the safety and efficacy of favipiravir in COVID-19 by reviewing published articles. We found favipiravir is effective, safe, and tolerated against COVID-19. More information is needed to determine long-term consequences, such as QT prolongation, hyperuricemia, and teratogenicity. Favipiravir interacts with other medications such as repaglinide, pyrazinamide, theophylline, acyclovir, warfarin, and methotrexate. Physicians should be aware when prescribing it.

Key words: Favipiravir, COVID-19, SARSCoV-2, antiviral drugs, pandemic.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.